Reversely, proliferation and/or motility of cancer cells also showed a decrease after LPA signalling through LPAR2 in melanoma (77), LPAR4 in pancreatic, colon, and head and neck cancer (75, 78, 79), LPAR5 in pancreatic cancer and melanoma (75, 80), and LPAR6 in colon cancer (78, 81). This evidence concerns the gene LPAR2 and melanoma.